Study to Assess the Efficacy and Safety of BDP HFA Nasal Aerosol in Patients 12 Years and Older With SAR
Status:
Completed
Trial end date:
2009-05-01
Target enrollment:
Participant gender:
Summary
This is a phase 2, randomized, double-blind, placebo-controlled, parallel-group, 2-week,
multi-center, dose-range-finding study in male or female patients (12 years and older) with
SAR.
Phase:
Phase 2
Details
Lead Sponsor:
Teva Branded Pharmaceutical Products R&D, Inc. Teva Branded Pharmaceutical Products, R&D Inc.